Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission a randomized clinical trial by Foell, Dirk et al.
ORIGINAL CONTRIBUTION
Methotrexate Withdrawal at 6 vs 12 Months
in Juvenile Idiopathic Arthritis in Remission
A Randomized Clinical Trial
Dirk Foell, MD
Nico Wulffraat, MD
























Angela Pistorio, MD, PhD
Alberto Martini, MD
Nicolino Ruperto, MD, MPH
Johannes Roth, MD
for the Paediatric Rheumatology
International Trials Organization
(PRINTO)
CHRONIC INFLAMMATORY DIS-eases are among the most rel-evant medical challenges.While these diseases have in-
creased in prevalence, many, includ-
ing rheumatoid arthritis, inflamma-
tory bowel disease, and juvenile
idiopathic arthritis (JIA), are now treat-
able.1-3 However, JIA often takes a re-
mitting disease course, and the long-
term outcome is not easy to predict.4-8
Therefore, physicians have to balance
the risk of doing too little (eg, with-
drawing medication and provoking
flares) vs the risk of doing too much (eg,
continuing medication despite a stable
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Context Novel therapies have improved the remission rate in chronic inflammatory
disorders including juvenile idiopathic arthritis ( JIA). Therefore, strategies of tapering
therapy and reliable parameters for detecting subclinical inflammation have now be-
come challenging questions.
Objectives To analyze whether longer methotrexate treatment during remission of
JIA prevents flares after withdrawal of medication and whether specific biomarkers
identify patients at risk for flares.
Design, Setting, and Patients Prospective, open, multicenter, medication-
withdrawal randomized clinical trial including 364 patients (median age, 11.0 years) with
JIA recruited in 61 centers from 29 countries between February 2005 and June 2006.
Patients were included at first confirmation of clinical remission while continuing medi-
cation. At the time of therapy withdrawal, levels of the phagocyte activation marker myeloid-
related proteins 8 and 14 heterocomplex (MRP8/14) were determined.
Intervention Patients were randomly assigned to continue with methotrexate therapy
for either 6 months (group 1 [n=183]) or 12 months (group 2 [n=181]) after induc-
tion of disease remission.
Main Outcome Measures Primary outcome was relapse rate in the 2 treatment
groups; secondary outcome was time to relapse. In a prespecified cohort analysis, the
prognostic accuracy of MRP8/14 concentrations for the risk of flares was assessed.
Results Intention-to-treat analysis of the primary outcome revealed relapse within 24
months after the inclusion into the study in 98 of 183 patients (relapse rate, 56.7%) in
group 1 and 94 of 181 (55.6%) in group 2. The odds ratio for group 1 vs group 2 was
1.02 (95% CI, 0.82-1.27; P=.86). The median relapse-free interval after inclusion was
21.0 months in group 1 and 23.0 months in group 2. The hazard ratio for group 1 vs
group 2 was 1.07 (95% CI, 0.82-1.41; P=.61). Median follow-up duration after inclu-
sion was 34.2 and 34.3 months in groups 1 and 2, respectively. Levels of MRP8/14 dur-
ing remission were significantly higher in patients who subsequently developed flares (me-
dian, 715 [IQR, 320-1110] ng/mL) compared with patients maintaining stable remission
(400 [IQR, 220-800] ng/mL; P=.003). Low MRP8/14 levels indicated a low risk of flares
within the next 3 months following the biomarker test (area under the receiver operating
characteristic curve, 0.76; 95% CI, 0.62-0.90).
Conclusions In patients with JIA in remission, a 12-month vs 6-month withdrawal
of methotrexate did not reduce the relapse rate. Higher MRP8/14 concentrations were
associated with risk of relapse after discontinuing methotrexate.
Trial Registration isrctn.org Identifier: ISRCTN18186313
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remission and thereby accepting the risk
of adverse effects). While evidence-
based advice for starting therapies in ac-
tive disease is available, no controlled
data exist to suggest the need for treat-
ment continuation after remission is
achieved.9
In the case of JIA, methotrexate is the
most widely used disease-modifying
drug.1,3,10,11 Remission can be induced
in most patients continuing medica-
tion (also referred to as “remission on
medication”5) using combined anti-
inflammatory treatment, and up to 50%
of such patients reach a continuous sta-
tus of remission after discontinuing
medication (also referred to as “remis-
sion off medication”5).7,12 However,
about half of the patients have flares af-
ter withdrawing or tapering methotrex-
ate—an intriguing ratio for statistical
analysis of follow-up studies. Continu-
ation of methotrexate for at least 12
months after induction of remission has
been proposed,11,13 although no con-
trolled prospective studies have inves-
tigated the effect of early discontinua-
tion of methotrexate treatment on the
rate of flares.
Laboratory markers currently in use
cannot detect residual inflammation
that influences the risk of flares when
stopping treatment; hence, clinicians
would benefit from improved molecu-
lar biomarkers of inflammation. My-
eloid-related protein (MRP) 8 (S100A8)
and MRP 14 (S100A9) are secreted by
activated phagocytes and form MRPs 8
and 14 heterocomplex (MRP8/14
[calprotectin]).14 In JIA, MRP8/14 has
been shown to be a marker of subclini-
cal disease activity not detectable by
clinical investigation or laboratory
tests.9,15 In this study we analyzed
whether the duration of methotrexate
therapy during clinical remission of JIA
influences the rate of flares after with-
drawal and hypothesized that patients




Patients with any subtype of JIA16 suc-
cessfully treated with methotrexate
were eligible for this study. The pa-
tients were included at first confirma-
tion of clinical remission while con-
tinuing medication, ie, after clinically
documented inactive disease for at least
3 months.5,7,12 According to the crite-
ria for inactive disease, the patients had
no joints with active arthritis; no fe-
ver, rash, serositis, splenomegaly, or
generalized lymphadenopathy attrib-
utable to arthritis; no active uveitis; no
elevation in erythrocyte sedimenta-
tion rate, C-reactive protein level, or
both attributable to arthritis; and no dis-
ease activity by physician’s global as-
sessment on a visual analog scale rang-
ing from 0 to 10 cm. At inclusion only
1 nonsteroidal anti-inflammatory drug
and methotrexate (maximum dose, 15
mg/m2 per week) were permitted. Ste-
roids had to be withdrawn at least 1
month prior to inclusion. Patients were
excluded if they had received intra-
articular corticosteroids, biologics, or
other disease-modifying drugs up to 3
months prior to inclusion. Data on race/
ethnicity were collected and racial/
ethnic groups recategorized in the phase
of the analysis as white, Hispanic, and
other. Race/ethnicity had no rel-
evance for subsequent analyses.
The study protocol was approved by
independent ethics committees at each
study site. Patients or their parents pro-
vided written informed consent. The
study complied with the Consolidated
Standards of Reporting Trials state-
ment and the Standards for Reporting
of Diagnostic Accuracy guidelines.17,18
Study Design
The study was designed as a prospec-
tive, open, multicenter, medication-
withdrawal randomized clinical trial.
Patients were included during clinical
remission while continuing medica-
tion at participating pediatric rheuma-
tology centers and were randomly as-
signed to 1 of 2 groups by the Pediatric
Rheumatology International Trials Or-
ganization (PRINTO) using a com-
puter-generated randomization sched-
ule. In group 1, patients discontinued
methotrexate (and nonsteroidal anti-
inflammatory drugs, if applicable) 6
months after inclusion if remission was
confirmed at that time. In group 2, pa-
tients discontinued therapy 12 months
after inclusion if remission was con-
firmed at that time. Clinical remission
after discontinuation of medication was
evaluated in both groups in further fol-
low-up examinations every 3 months
over at least another year. Stable remis-
sion was defined as the absence of any




Patients were evaluated using the pre-
liminary criteria for inactive disease and
clinical remission of JIA.5 In addition,
data were collected on subtype, dis-
ease onset and duration, time taking
methotrexate, dosage, other medica-
tions, morning stiffness, or complica-
tions. Disease flare was defined as oc-
currence of any sign of active arthritis
and/or active systemic symptoms, ie,
when any of the criteria for inactive dis-
ease was no longer met. The clinical as-
sessments were made by experienced
pediatric rheumatologists at each visit.
Laboratory Examinations
Serum concentrations of MRP8/14 were
determined by an in-house sandwich
enzyme-linked immunosorbent assay as
previously reported.19 Interassay and in-
tra-assay reliability were 9.7% and 8.2%,
respectively. Serum MRP8/14 concen-
trations were analyzed once during
clinical remission at the time treat-
ment with methotrexate was stopped.
The analyzing laboratory in Muenster
was blinded for patients’ characteris-
tics. Erythrocyte sedimentation rate (by
Westergren method) and C-reactive
protein level (by nephelometry) were
standardized based on the normal val-
ues provided by each local laboratory
as previously described.20
Statistical Analysis
The primary outcome of the study was
the relapse rate. The difference be-
tween flare rates in both treatment
groups was determined for both the in-
tention-to-treat population and the per-
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protocol cohort. Intention-to-treat
analyses were performed, including all
randomized patients and evaluating the
flare rate within 2 years after the pa-
tients’ inclusion into the study. In per-
protocol analyses, the flare rate within
1 year after methotrexate discontinu-
ation was evaluated, including pa-
tients who discontinued methotrexate
treatment according to the protocol.
Consequently, the intention-to-treat
analysis of the primary outcome evalu-
ated the relapse rate within 24 months
after the patients’ inclusion into the
study. Missing values were imputed
using multiple imputation. In a corre-
sponding per-protocol analysis, the re-
lapse rate over at least 1 year after
methotrexate discontinuation was ana-
lyzed. Differences between treatment
groups were evaluated by a 2-sided 2
test at an  level of .05. A flare rate of
50% within 1 year after withdrawal of
therapy was assumed. Thus, power
analysis revealed that a total of 193
evaluable patients were required to pro-
vide an 80% power of detecting treat-
ment differences of at least 20%.
The secondary outcome was time to
relapse. A prespecified observational co-
hort analysis assessed the prognostic ac-
curacy of MRP8/14 concentration for
risk of flares.
Demographic and baseline charac-
teristics were summarized using de-
scriptive statistics. Data are given as
mean or median as well as range, in-
terquartile range (IQR), or 95% confi-
dence interval (CI). The 2-sided Mann-
Whitney U test was applied to analyze
differences of quantitative parameters
between groups of patients. Qualita-
tive parameters were evaluated with the
2 test.
Survival analyses were performed,
comprising Kaplan-Meier plots and log-
rank tests as well as hazard ratios and
associated CIs based on a proportional
hazards model. The proportional haz-
ards assumption was verified using the
Grambsch-Therneau residual-based test.
Survival analyses were performed in pa-
tients who received an analysis of se-
rum MRP8/14 level at the time treat-
ment was discontinued during
remission, to determine the difference
between the flare rates in patients with
high vs low MRP8/14 levels. Biased re-
sults due to differences between JIA sub-
types were excluded by Cox models with
disease subtypes as covariable. Classi-
fication and regression tree analysis were
used to determine the optimal cutoff
level for MRP8/14.21 Receiver operat-
ing curves (ROCs) were used to deter-









Female sex, No. (%) 119 (65) 123 (68) .55
Age at inclusion, y 11.2 (2-18) 10.7 (2-18) .81
Age at disease onset, y 5.4 (1-16) 6.1 (1-15) .43
Disease duration, y 3.2 (0-13) 3.0 (0-16) .62
Juvenile idiopathic arthritis subtypes, No. (%)
Persistent oligoarthritis 54 (30) 42 (23) .17
Extended oligoarthritis 34 (19) 22 (12) .09
Polyarthritis, negative rheumatoid factor 54 (30) 81 (45) .003
Polyarthritis, positive rheumatoid factor 9 (5) 8 (4) .82
Systemic-onset juvenile idiopathic arthritis 14 (8) 21 (12) .20
Enthesitis-related arthritis 7 (4) 3 (2) .34
Psoriatic arthritis 11 (6) 4 (2) .07
Treatment and laboratory values at inclusion
Methotrexate dose, mg/m2 per wk 10.0 (1-17) 11.0 (4-20) .11
Time taking methotrexate, y 1.3 (0-12) 1.4 (0-10) .50
Taking nonsteroidal anti-inflammatory
drugs, No. (%)
76 (42) 60 (33) .12
Erythrocyte sedimentation rate, mm/h 9 (0-20) 8 (0-19) .48
C-reactive protein, mg/L 1.0 (0-2.5) 0.9 (0-2.2) .62
Laboratory values at withdrawal
Erythrocyte sedimentation rate, mm/h 9 (5-17) 8 (4-19) .78
C-reactive protein, mg/L 0.3 (0-1.4) 0.2 (0-2.0) .70
MRP8/14, ng/mL 510 (60-2640) 480 (110-3310) .94
Abbreviation: MRP8/14, myeloid-related proteins 8 and 14 heterocomplex.
SI conversion factor: To convert C-reactive protein values to nmol/L, multiply by 9.524.
aGroup 1 comprised patients discontinuing methotrexate after 6 months in remission; group 2, those discontinuing
methotrexate after 12 months in remission.
Figure 1. Study Flow
159 Included in per-protocol analysis
173 Included in primary analysis
3 Lost to follow-up within 1 y
after stopping therapy
2 Lost to follow-up before
stopping therapy
8 Lost to follow-up after stopping
therapy and within 2 y after
randomization
183 Randomized to continue
methotrexate for 6 mo
162 Continued methotrexate
for 6 mo as randomized
19 Had flares before stopping
therapy
2 Lost to follow-up before
stopping therapy
129 Included in per-protocol analysis
169 Included in primary analysis
6 Lost to follow-up within 1 y
after stopping therapy
4 Lost to follow-up before
stopping therapy
8 Lost to follow-up after stopping
therapy and within 2 y after
randomization
181 Randomized to continue
methotrexate for 12 mo
135 Continued methotrexate
for 12 mo as randomized
42 Had flares before stopping
therapy
4 Lost to follow-up before
stopping therapy
364 Patients with remission while
continuing medication randomized
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mine accuracy. As a summary statistic,
the area under the ROC curve was cal-
culated. This area is equal to the prob-
ability that the MRP8/14 marker will
rank a randomly chosen patient who will
experience a flare higher than a ran-
domly chosen patient who will not.
Statistical analyses were performed
using SAS version 9.2 (SAS Institute Inc,
Cary, North Carolina). All reported P
values are 2-sided and are considered
significant at P .05.
RESULTS
Baseline Patient Characteristics
A total of 364 patients in remission
while continuing medication were en-
rolled in 61 PRINTO study centers from
29 countries between February 2005
and June 2006. The patients were ran-
domized at enrollment to continue
therapy for either 6 (group 1) or 12
(group 2) months. Differences in demo-
graphic characteristics and disease para-
meters at baseline between the 2 groups
have been checked for statistical sig-
nificance (TABLE 1). Only one JIA sub-
type, polyarthritis with negative rheu-
matoid factor, proved not equally
distributed in both groups. Conse-
quently, to prevent biased results, all
subsequent analyses were addition-
ally confirmed in multivariate model ap-
proaches adjusting for JIA subtype.
Randomization and Drug
Withdrawal
At inclusion, 183 patients were ran-
domized into group 1 and 181 into
group 2. Six patients (1.7%) were lost
to follow-up before stopping treat-
ment; in 61 (16.8%), a flare occurred
during the period of remission while
continuing medication. The rate of
flares during the period while continu-
ing medication was comparable in both
groups when correcting for time at risk,
ie, 17.9 (95% CI, 11.4-28.1) and 21.9
(95% CI, 16.2-29.7) per 1000 patient-
months in groups 1 and 2, respec-
tively. In group 1, 162 patients with-
drew methotrexate and entered a phase
of remission after discontinuing medi-
cation. In group 2, 135 patients reached
this point (FIGURE 1). At the time of
withdrawal, serum was collected when-
ever possible and stored frozen for
MRP8/14 analysis.
Analysis of the Primary
and Secondary Outcome
Intention-to-treat analyses of the pri-
mary outcome revealed relapse within
24 months after the inclusion into the
study in 98 of 183 patients (relapse rate,
56.7%) in group 1 and 94 of 181
(55.6%) in group 2 (odds ratio, 1.02;
95% CI, 0.82-1.27; P=.86). This re-
sult was qualitatively confirmed in a
multivariate model approach adjust-
ing for JIA subtype. The median relapse-
free interval after inclusion was 21.0
months in group 1 and 23.0 months in
group 2. The hazard ratio for group 1
vs group 2 was 1.01 (95% CI, 0.82-
1.41; P=.61). Median follow-up dura-
tion after inclusion was 34.2 and 34.3
months in groups 1 and 2, respectively.
In the 297 patients who stopped
therapy while in remission, 63 of 162
(39.6%) in group 1 and 51 of 135
(39.5%) in group 2 had a flare within
1 year. Thus, a per-protocol analysis of
the primary outcome revealed an odds
ratio of 1.00 (95% CI, 0.62-1.61;
P=.99). Because the number of flares
occurring later than 12 months after
withdrawal differed between the groups
(25 in group 1 vs 8 in group 2), there
were 88 flares among 162 patients
(54%) in group 1 and 59 flares among
135 patients (44%) in group 2 over the
whole study period. These values are
influenced by the fact that beyond 12
months of follow-up after withdrawal,
patients in group 1 were censored later
than those in group 2. Median fol-
low-up thus differed considerably, con-
stituting 28.2 (IQR, 24.5-34.2) months
in group 1 and 22.6 (IQR, 16.8-27.3)
months in group 2. However, the over-
all flare rates were not different, with
40.2 (95% CI, 31.4-51.5) and 40.3 (95%
CI, 30.6-53.0) per 1000 person-
months in groups 1 and 2, respec-
tively (P=.44). The intention-to-treat
sensitivity analysis of the relapse-free
interval on the whole study popula-
tion revealed no difference in rate of
flares between the groups (FIGURE 2).
The flare rates at 12 months were
considered for performing signifi-
cance tests as well as the per-protocol
analysis (FIGURE 3). The timing of dis-
continuation of methotrexate during re-
mission had no effect on the likeli-
hood of flares within 1 year after
discontinuation of treatment.
Assessment of Residual Disease
Activity by MRP8/14 Level
Of the 297 patients who stopped tak-
ing methotrexate, serum was available
Figure 2. Analysis of Flare Rates
100 Log-rank P = .61
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Group 1 comprised patients discontinuing methotrex-
ate after 6 months in remission; group 2, those dis-
continuing methotrexate after 12 months in remis-
sion. Survival time starts at inclusion into the study and
was performed without restricting follow-up. There
was no difference in the rate of flares between the
treatment groups. The y-axis shows the proportion of
patients with flares after discontinuing medication. CI
indicates confidence interval; HR, hazard ratio.
Figure 3. Per-Protocol Analysis of Flare
Rates
100 Log-rank P = .97




































Group 1 comprised patients discontinuing metho-
trexate after 6 months in remission; group 2, those
discontinuing methotrexate after 12 months in
remission. Analysis was restricted to a follow-up
of 12 months after withdrawal of therapy. There
was no difference in the rate of flares between the
treatment groups. The y-axis shows the propor-
tion of patients with flares after discontinuing
medication. CI indicates confidence interval; HR,
hazard ratio.
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for 188. These patients had a serum
analysis for MRP8/14 level during re-
mission (64% in group 1 and 63% in
group 2). The patients were well rep-
resentative of the total study popula-
tion (TABLE 2). At this point, erythro-
cyte sedimentation rates and C-reactive
protein levels were within normal
ranges. The median MRP8/14 levels
were higher than in healthy controls but
comparable to patients with juvenile ar-
thritis in clinical remission, as ana-
lyzed in previous studies.15,22 Because
MRP8/14 is a marker of phagocyte ac-
tivation, this indicates ongoing innate
immune reactions in at least some pa-
tients. Although all patients were in re-
mission at this point according to the
remission criteria on clinical grounds
and considering routine laboratory
parameters, MRP8/14 as molecular
marker of innate immunity suggested
that not all patients were in immuno-
logical remission.
Predictive Validity of MRP8/14
Levels for Risk of Flare
The flare rate in the patients undergo-
ing biomarker analysis was not differ-
ent from that in the overall study
population (TABLE 3). We tested the
hypothesis that patients with subclini-
cal disease activity, indicated by
higher MRP8/14 serum concentra-
tions during remission while continu-
ing medication, were more likely to
experience a flare during follow-up
while in remission after discontinuing
medication. Patients with stable
remission had a median MRP8/14
level of 400 (IQR, 220-800) ng/mL,
while patients with flares had a
median MRP8/14 level of 715 (IQR,
320-1110) ng/mL (P=.003). The haz-
ard ratio was highest when comparing
levels of 690 (IQR, 270-895) ng/mL
or greater vs less than 690 ng/mL
(2.24; 95% CI, 1.39-3.62; P .001). A
log-rank analysis confirmed the differ-
ence of flare rates at this cutoff
(FIGURE 4) , whi le ROC curves
revealed a sensitivity of 69% and a
specificity of 66% for predicting
flares. In multivariate Cox regression
analyses, potential confounders
beyond MRP8/14 concentrations
were included (ie, treatment group,
sex, age at disease onset, and JIA sub-
type). In the multivariate model, sig-
nificant interactions of any regressor
variables with MRP8/14 could be
excluded.
The flare rates per 1000 patient-
months were significantly higher in
individuals with MRP8/14 levels of
690 ng/mL or greater vs less than 690
ng/mL when compared at 3, 6, 12, or
24 months (Table 3). More detailed
analyses showed that higher MRP8/14
levels especially relate to the risk of
early flares within the following 3
months (FIGURE 5). The group of
patients with flares within 3 months
had a median MRP8/14 level of 1260
(IQR, 850-1900) ng/mL. The accu-
racy of the biomarker was especially
useful for the prediction of early
relapses within this short time
(TABLE 4). Considering flares within
the next 3 months following the
laboratory test, the MRP8/14 marker
showed an area under the ROC curve
of 0.76 (95% CI, 0.62-0.90).
COMMENT
Longer continuation of methotrexate
therapy after induction of remission
while continuing medication does not
generally improve the stability of re-
mission after discontinuing medica-
tion in JIA. The risk of relapsing dis-
ease remains similar after treating
patients longer. A significant differ-
ence in follow-up times between the
study groups beyond 1 year resulted in
a disadvantage for the 6-month group
and impeded a comparison of later
flares. However, that the overall flare
rates were not significantly different be-
tween the groups argues strongly
against a late difference that would not
have been detected within the 1 year fol-
low-up period. Indeed, most of the
















Persistent oligoarthritis 59 (31)














Psoriasis arthritis 8 (4)
Abbreviation: MRP8/14, myeloid-related proteins 8 and 14
heterocomplex.




Value690 ng/mL 690 ng/mL
Flares per patient, No./total (%)
Within 0-3 mo 2/113 (2) 13/75 (17) .001
Within 0-6 mo 13/113 (12) 22/75 (29) .004
Within 0-12 mo 31/113 (27) 37/75 (49) .004
Within 0-24 mo 39/113 (35) 45/75 (60) .001
After 24 mo 6/50 (12) 2/14 (14) .99
Overall 45/113 (40) 47/75 (63) .004
Flares per 1000 patient-months
Within 0-3 mo 5.9 60.3 .001
Within 0-6 mo 19.9 57.3 .001
Within 0-12 mo 26.0 57.0 .001
Within 0-24 mo 19.5 48.2 .001
After 24 mo 11.2 39.8 .22
Overall 17.7 47.8 .001
Abbreviation: MRP8/14, myeloid-related proteins 8 and 14 heterocomplex.
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flares after withdrawal occurred within
the first 6 months, with only a few oc-
curring later than 12 months after stop-
ping therapy. Interestingly, there was
also a background risk of flares that was
not prevented during the mainte-
nance therapy, but the flare rate dur-
ing remission while continuing medi-
cation was significantly lower than that
during remission after discontinuing
medication. Therefore, it cannot be rec-
ommended that methotrexate therapy
be continued in all patients for longer
than 6 months after remission is in-
duced. The current definition of remis-
sion may be refined, adding “immuno-
logical remission” as a status that will
be robust enough to last after discon-
tinuing medication.
While erythrocyte sedimentation rate
and C-reactive protein level are not sen-
sitive enough to assess residual inflam-
matory joint disease, MRP8/14 is a
marker of local disease activity, and
analysis of MRP8/14 levels detects sub-
clinical inflammation that would ex-
clude immunological remission.14,23
MRP8/14 is a member of the family of
“danger signals” and an endogenous ac-
tivator of toll-like receptor 4, which is
involved in innate immune mecha-
nisms in inflammatory conditions such
as arthritis and infections.24,25 It is spe-
cifically secreted from activated phago-
cytes at local sites of inflammation and
is a novel therapeutic target in autoim-
munity.26,27
Flares after withdrawal of therapy
are most likely related to the fact that
the local disease process is not com-
pletely resolved, even though clinical
impression and acute phase reactants
suggest remission. Levels of MRP8/14
reflect subclinical inflammation that
will influence the risk for flares, espe-
cially within the following 3 months.
In the clinical setting it is clearly use-
ful to use such a biomarker of syno-
vial inflammation, because levels less
than 690 ng/mL make it relatively
unlikely that subclinical disease activ-
ity is present at the time the test is
performed (negative predictive value,
98%). The likelihood of disease activ-
ity that could progress into a full-
blown disease flare over the following
3 months is small (negative likelihood
ratio, 0.2), which helps with deciding
to stop treatment.
Previous studies have revealed that
the probability of stable remission is
similar among subtypes of JIA. Pa-
tients with polyarticular disease and
positive rheumatoid factor may have a
slightly higher risk for flares, but this
group was very small in our study. Be-
cause across all subtypes approxi-
mately 50% of patients relapse and 50%
stay in remission after discontinua-
tion of therapy,5,7,12 JIA is an ideal sta-
tistical model to study the flare risk dur-
ing remission after discontinuing
medication. However, our data are of
general relevance, because many
chronic inflammatory diseases regu-
larly take a relapsing course. Treat-
ment over years is often necessary, even
though patients may respond to the ini-
tial therapies. Sufficient advice exists for
starting therapies once the diagnosis is
established or for escalating treatment
if the therapy is not sufficient to in-
duce remission.2 However, in clinical
practice physicians are frequently faced
with the question of what to do with
patients who are clinically well after in-
duction of remission. Physicians have
to decide whether continuation of drug
therapy is meaningful, because it may
maintain inactive disease and induce a
more stable remission that may last even
after later withdrawal of treatment. Be-
sides methotrexate therapy in JIA, ex-
pert opinions for the continuation of
treatment during a state of remission
while continuing medication exist for
inflammatory bowel disease, for which
continuation of azathioprine for more
than 3 years while in remission is rec-
ommended.28 In rheumatoid arthritis,
for which remission after discontinu-
ing medication is now the accepted goal
of management, the duration of treat-
ment during remission while continu-
ing medication is a matter of debate.29
In pediatric autoimmune hepatitis,
therapy continued for at least 1 to 2
years while in complete remission has
been proposed.30 However, the dura-
tion of maintenance therapy in JIA dur-
Figure 5. MRP8/14 as Molecular Marker of





























Patients with a flare over the whole study period had
significantly higher levels of myeloid-related proteins
8 and 14 heterocomplex (MRP8/14) than patients who
remained in stable remission (P=.003). The 92 pa-
tients with flares were further divided into subgroups
of patients who had early flares within 6 months (n=35)
or 3 months (n=15) after the biomarker analysis. When
restricting to the 3-month follow-up, MRP8/14 lev-
els of patients with relapse showed only little overlap
with values from patients who remained in stable re-
mission (P=.001 within 6 months; P .001 within 3
months). The upper and lower bounds of each box
indicate the 25th and 75th percentile, respectively;
heavy lines within the box, the median; whiskers, the
10th and the 90th percentile. Dashed line indicates
the cutoff at 690 ng/mL. P values report a compari-
son with patients without relapses while in remission
after discontinuing medication, ie, in stable remission
(Mann-Whitney U test).
Figure 4. Analysis of Flares Using
MRP8/14 as a Molecular Marker of
Relapse Risk
100 Log-rank P <.001
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Survival analysis confirmed the significant differ-
ence of flare rates between patients with myeloid-
related proteins 8 and 14 heterocomplex (MRP8/
14) levels of 690 ng/mL or greater compared with
those with lower levels. The analysis considered a
follow-up of 12 months after withdrawal of ther-
apy, which was the time when the biomarker
analysis was performed. The y-axis shows the pro-
portion of patients with flares after discontinuing
medication. CI indicates confidence interval; HR,
hazard ratio.
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ing remission while continuing medi-
cation was never before tested in a
controlled trial.
Although data regarding the pri-
mary outcome of this study are clear,
our study has some limitations. The
real length of remission can be deter-
mined only in patients who experi-
enced a relapse during the study. If
patients did not show a flare during
the study, then the total length of
remission cannot be determined,
because it may even last for the
remaining years of life. Another con-
cern is the variety of disease subtypes.
As in previous studies, patients in our
study with systemic JIA had higher
MRP8/14 levels even while in stable
remission, but the patients with sys-
temic JIA had the lowest relapse rate.
We thoroughly analyzed all data with
regard to disease subtype as a con-
founder and could exclude that sub-
groups did influence the overall
results. However, because of the small
numbers, cutoff MRP8/14 levels for
different subtypes cannot be provided
from our study. Also, generalization
from our data on the biomarker to all
patients undergoing other therapies
such as biologics cannot be made.
Lastly, the secondary outcome of the
biomarker findings are based on a
cohort analysis, which weakens the
validity strength, and the results will
eventually need to be confirmed in
larger cohorts. This limitation espe-
cially relates to the determination of
the cutoff value of 690 ng/mL, which
has to be confirmed in future trials.
In summary, a 12-month with-
drawal of methotrexate compared with
a 6-month withdrawal did not reduce
the relapse rate in patients with JIA in
remission. Higher MRP8/14 concen-
trations were associated with the risk
of relapse after discontinuing metho-
trexate. These data indicate a need for
the stratification of patients with
chronic inflammatory diseases to en-
sure that the intensity of treatment is
adjusted to the patients’ individual
needs.
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